METHODS OF ADMINISTERING RIFAXIMIN WITHOUT PRODUCING ANTIBIOTIC RESISTANCE
Methods of administering a composition comprising rifaximin to a subject in need thereof are provided, wherein the methods do not increase development of rifampicin resistance to a Staphylococcus spp. Methods of reducing the development of rifampicin resistance to a Staphylococcus spp. are also provided, comprising administering a composition comprising rifaximin to a subject in need thereof.
1 . A method of reducing rifampicin-resistance Staphylococcus spp. organisms in a subject in thereof, comprising administering a composition comprising a therapeutically effective amount of rifaximin to the subject.
2 . The method of claim 1 , wherein reducing results in a reduction in the number of rifampicin-resistant Staphylococcus spp. compared to a pre-treatment baseline number.
3 . The method of claim 2 , wherein the reduction in the number of rifampicin-resistant Staphylococcus spp. relative to baseline is determined by culturing stool samples obtained from the subject prior and subsequent to administration of the composition.
4 . The method of claim 1 , wherein the threshold mean inhibitory concentration of rifampicin for the Staphyloccocus spp. organism is less than about 2.5 μg/mL.
5 . The method of claim 1 , wherein the rifaximin is administered at a dose of about 50 mg to about 6000 mg per day.
6 . The method of claim 1 , wherein the rifaximin is administered at a dose of between about 100 mg and about 6000 mg; from between about 50 mg and about 2500 mg BID; from between about 50 mg and about 2000 mg TID; 200 mg TID; 200 mg BID or 200 mg QD.
7 . The method of claim 1 , wherein the rifaximin is administered at a dose of about 550 mg, 600 mg or 1650 mg TID, QD or BID.
8 . The method of claim 1 , wherein the composition is administered for between about 1 week and about 24 months.
9 . The method of claim 1 , wherein the composition is administered the composition for about 10 days.
10 . The method of claim 1 , wherein the subject is suffering from a bowel disease selected from the group of: an inflammatory bowel disease (IBD), hepatic encephalopathy (HE), enteritis, colitis, irritable bowel syndrome (IBS), diarrhea-predominant irritable bowel syndrome (d-IBS), non-constipation-predominant irritable bowel syndrome (non-C IBS), traveler's diarrhea (TD), a Clostridium difficile infection (CDI), diverticular disease, fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit/hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), small intestinal bacterial overgrowth, chronic pancreatitis, and pancreatic insufficiency.
11 . The method of claim 10 , wherein the inflammatory bowel disease is selected from the group of: Crohn's Disease and ulcerative colitis.
12 . The method of claim 10 , wherein the enteritis is caused by radiation therapy or chemotherapy.
13 . The method of claim 1 , further comprising administering a gastrointestinal (GI) cleanser to the subject prior to administration of the composition comprising rifaximin.
14 . The method of claim 13 , wherein the gastrointestinal cleanser is administered between about 1 to about 90 days prior to administration of the composition.
15 . The method of claim 14 , wherein the administration of the gastrointestinal cleanser is between about 1 to about 60 days; between about 1 to about 30 days; between about 1 to about 24 days; between about 1 to about 14 days; between about 1 to about 10 days; between about 1 to about 7 days; between about 1 to about 5 days; between about 1 to about 4 days; between about 1 to about 3 days; or between about 1 to about 2 days prior to administration of the composition.